Application of S100A9 in preparation of medicine for preventing or treating radioactive intestinal injury caused by ionizing radiation

By using S100A9 as the active ingredient of drug, it promotes the regeneration of intestinal stem cells and proliferation of intestinal organoids, and solves the problem of radioactive intestinal damage caused by ionizing radiation, significantly improves the survival rate and intestinal damage repair effect of mice, and prevents and treats radioactive intestines. Injury provides new targets and ideas.

CN119033916APending Publication Date: 2024-11-29THE NAVAL MEDICAL UNIV OF PLA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411247544.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Radioactive intestinal damage caused by ionizing radiation is an extremely fatal pathological injury, and it is difficult to effectively prevent and treat the existing technology, especially due to the lack of effective targets and pathways in the complex damage process caused by the sensitivity of intestinal stem cells and the activation of inflammation.

Method used

Using S100A9 as the only active ingredient, the mouse exogenous recombinant protein rm-S100A9 is used to promote the regeneration of intestinal stem cells and the proliferation and differentiation of intestinal organoids, providing protective effects, reducing radiation sensitivity and reducing intestinal tract damage.

Benefits of technology

Studies have shown that S100A9 KO mice have lower survival rates and more severe intestinal damage. After the administration of rm-S100A9, the survival rate and intestinal organoid generation ability of mice were significantly improved, and the regeneration of intestinal stem cells was promoted. It provides potential new targets and ideas for preventing and treating radioactive intestinal injuries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033916A_ABST
    Figure CN119033916A_ABST
Patent Text Reader

Abstract

The invention discloses an application of S100A9 in preparation of a medicine for preventing or treating intestinal radiation injury, and by means of mouse intestinal organoid culture, it is found that exogenous administration of S100A9 recombinant protein has a protection effect on radiation injury of intestinal organoids. The invention provides an application research and development prospect of the S100A9 for preventing and treating the radiation intestinal injury, and provides a potential new target for research and development of medicines for preventing and treating the radiation intestinal injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to an application of S100A9 in preparing a medicine for preventing or treating radiation-induced intestinal damage caused by ionizing radiation. Background Art

[0002] Ionizing radiation can cause radiation damage to various tissues, among which the intestinal tissue is extremely sensitive to ionizing radiation. It is a common pathological damage in casualties after large-dose nuclear radiation exposure. When the exposure dose is ≥10.0Gy, it can cause degeneration and necrosis of the intestinal tissue of the exposed person, causing intestinal radiation sickness. The injured generally die within a short period of time (5-10 days) after exposure, and the mortality rate is 100%.

[0003] There is still a long way to go to break through the bottleneck problem of the prevention and treatment of radiation-induced intestinal injury. On the one hand, ionizing radiation damages biological macromolecules (DNA, proteins, etc.) through direct and indirect effects, leading to the death of intestinal epithelial cells and crypt stem cells, damage to the intestinal barrier, and causing digestion and absorption disorders, water and acid-base imbalance, and even bacterial displacement, leading to body failure. On the other hand, when the intestine is exposed to large doses of ionizing radiation, it will cause swelling and apoptosis of microvascular endothelial cells, release a large number of inflammatory factors, form microthrombi, and then lead to ischemia and hypoxia of intestinal tissue, aggravating intestinal damage. It can be seen that the occurrence of radiation-induced intestinal injury is a complex process in which cell death and inflammatory activation alternate. In-depth research on the mechanism of radiation-induced intestinal injury and the exploration of new targets and new ways to prevent and treat radiation-induced intestinal injury are the key to breaking through the bottleneck problem of radiation-induced intestinal injury.

[0004] Intestinal epithelial cells ensure that the intestine fulfills important functions such as absorption, secretion and barrier function. The intestinal epithelium is renewed approximately every 5 days, and this renewal is completed by intestinal stem cells located at the bottom of the crypts. Intestinal stem cells are mixed with Paneth cells and are marked by the expression of several markers such as Lgr5. Intestinal stem cells are rapidly activated in response to stress injury, allowing for a rapid and effective restoration of damaged epithelial cells. Intestinal tissue is extremely sensitive to radiation, and exposure to high doses of radiation can lead to severe intestinal damage and death of intestinal stem cells.

[0005] The continuous regeneration of intestinal epithelial cells emphasizes the important role of intestinal stem cells in intestinal organization, which requires a tightly regulated balance between intestinal stem cell proliferation and differentiation. Intestinal stem cells located at the bottom of the crypts migrate upward and differentiate into all different types of mature epithelial cells to maintain the homeostasis of the intestinal epithelium under stable conditions. Since intestinal epithelial cells are in direct contact with pathogenic environmental factors, intestinal stem cells are susceptible to epithelial damage induced by chemicals, pathogens, or irradiation. When exposed to stimuli such as irradiation and pathogens, the intestine must respond actively to maintain epithelial integrity. Intestinal stem cells are very sensitive to radiation. A common outcome of radiation-induced intestinal damage is the loss of Lgr5 intestinal stem cells. However, there is more than one type of intestinal stem cell that plays an important role in epithelial damage. When Lgr5 intestinal stem cells are exhausted, Bmi1 cells take on intestinal stem cell properties and rapidly revert to Lgr5 intestinal stem cells to maintain intestinal homeostasis. These re-emerging Lgr5 stem cells have been shown to be essential for epithelial repair after radiation therapy, as Lgr5 intestinal stem cells are required for epithelial recovery after radiation therapy.

[0006] S100A9, the full name of which is S100 calcium-binding protein A9 (NCBI Reference Sequence: NC_000069.7), plays an important role in the regulation of inflammatory processes and immune responses ( G, Koenis DS, de Camp L, et al. S100A9 Links Inflammation and Repair in Myocardial Infarction. CircRes. 2020; 127(5): 664-676.). S100A8 and S100A9 belong to a family of 25 homologous low molecular weight intracellular calcium binding proteins that show tissue and cell-specific expression. They are characterized by two different EF-hand (helix-loop-helix) calcium binding domains connected by a hinge region. The N-terminal Ca2+ binding domain has a lower affinity than the typical C-terminal domain, which allows for a functionally important second messenger effect that depends on intracellular Ca2+ levels (Biswas AK, Han S, Tai Y, et al. Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer. Cancer Discov. 2022; 12(4): 1002-1021.). Both proteins can be induced simultaneously by several mediators in monocytes, endothelial cells, keratinocytes or epithelial cells, including LPS, TNFα, IL1α, IL-1β, IL-10 or IL-22. Summary of the invention

[0007] The purpose of the present invention is to provide an application of S100A9 in preparing a medicine for preventing or treating radiation-induced intestinal damage caused by ionizing radiation.

[0008] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0009] The first aspect of the present invention provides a use of S100A9 in the preparation of a drug for preventing or treating radiation-induced intestinal damage caused by ionizing radiation.

[0010] The ionizing radiation is the use of 60 Co γ-ray irradiation.

[0011] The irradiation dose of the ionizing radiation is 8.5 Gy, and the dose rate is 1.0 Gy / min.

[0012] The invention provides an application of S100A9 in the preparation of a medicine for preventing or treating radiation-induced intestinal damage caused by ionizing radiation, wherein S100A9 is used as the sole active ingredient.

[0013] The second aspect of the present invention provides a pharmaceutical composition, which is made of an active ingredient and a pharmaceutically acceptable excipient; wherein the active ingredient is the above-mentioned S100A9.

[0014] Furthermore, the pharmaceutical composition of the present invention is used in combination with other drugs for preventing or treating radiation-induced intestinal damage caused by ionizing radiation.

[0015] When mice are exposed to radiation, ionizing radiation damages biomacromolecules (DNA, proteins, etc.) through direct and indirect effects, leading to the death of intestinal epithelial cells and crypt stem cells, damage to the intestinal barrier, digestion and absorption disorders, water and acid-base imbalance, and even bacterial displacement, leading to body failure and death. When intestinal organoids are exposed to radiation, the efficiency of crypts generating organoids decreases, resulting in smaller organoids and lower budding rates.

[0016] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0017] The present invention provides the use of S100A9 in the preparation of a drug for preventing or treating intestinal radiation damage. Studies have found that radiation damage in S100A9 KO mice is aggravated. Animal experiments have shown that after 8.5Gy whole-body irradiation, the survival rate of S100A9 KO mice is lower and the radiation sensitivity is significantly increased. HE staining of the small intestinal tissue was performed, and it was found by observing the pathological sections that compared with the control group, the small intestinal villi in the S100A9 KO group were broken and shortened, the number was reduced, the morphology was abnormal, the mucosa was thinned, and the crypt epithelial cells were reduced.

[0018] Through the culture of mouse intestinal organoids, it was found that exogenous administration of S100A9 recombinant protein (rm-S100A9) has a protective effect on radiation damage to intestinal organoids. This shows that S100A9 has a protective effect on radiation damage to the mouse small intestine. The present invention proposes the application and research prospects of S100A9 in preventing and treating radiation-induced intestinal damage, and provides a potential new target for the research and development of drugs for preventing and treating radiation-induced intestinal damage.

[0019] The present invention provides that S100A9 KO can significantly reduce the survival rate of mice after irradiation and aggravate the intestinal damage suffered by mice after irradiation, and exogenous administration of rm-S100A9 can promote the proliferation and differentiation of mouse intestinal organoids after irradiation, and can effectively promote the regeneration of mouse intestinal stem cells. The present invention provides new targets and ideas for the prevention and treatment of radiation intestinal damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a schematic diagram of the survival period and intestinal damage degree of S100A9 KO mice after radiation.

[0021] Figure 2 This is a schematic diagram of the results of exogenous administration of rm-S100A9 to mouse intestinal organoids and extraction of intestinal organoid RNA for QT-PCR.

[0022] Figure 3 This is a schematic diagram of the results of exogenous administration of rmS100A9 to mouse intestinal organoids and extraction of intestinal organoid RNA for QT-PCR after blocking the Notch signaling pathway. DETAILED DESCRIPTION

[0023] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0024] Example 1

[0025] S100A9 KO mice have more severe radiation damage

[0026] 8-week-old male SPF-grade C57BL / 6 mice were purchased from Shanghai Jihui Experimental Animal Co., Ltd., and S100A9 KO mice were purchased from Saiye Biotechnology Co., Ltd. The mice were divided into a control group WT group and an experimental group S100A9 KO group. The mice were given a single systemic 60 Coγ-ray irradiation, the irradiation dose was 8.5Gy, the dose rate was 1Gy / min. After irradiation, the mice were given sterile water and mouse food, and the survival of the mice was observed for 30 days, and the survival curve was drawn. The WT group and the S100A9 KO group mice were given a single whole-body 60Coγ-ray irradiation was performed with a dose of 9.5 Gy and a dose rate of 1 Gy / min. 3.5 days after irradiation, the small intestinal tissues of mice were collected for pathological HE staining analysis.

[0027] The steps of pathological HE staining are as follows:

[0028] 1. Fixation: After killing the mouse by dislocating the neck, soak it in a 75% alcohol tank for a while, open the mouse's abdominal cavity, cut off 1 cm of the small intestine near the stomach, and then cut it open longitudinally. Rinse it with PBS and fix the obtained tissue specimen in 10% neutral buffered formalin.

[0029] 2. Dehydration: Dehydrate the fixed tissue specimens in ethanol solutions (70%, 85% and 95% ethanol in sequence) to remove water from the tissues. The time in each ethanol solution is 1 hour.

[0030] 3. Transparent and embedding: Place the small intestinal tissue in the transparent agent xylene I and II for transparent treatment, then place it in melted paraffin and put it in a wax melting box for heat preservation. Embed it after the paraffin is completely immersed in the small intestinal tissue, and the paraffin will solidify into a block after cooling.

[0031] 4. Slicing, baking and dewaxing: Fix the embedded and cooled paraffin tissue blocks on a microtome and cut them into thin slices with a thickness of 5 μm.

[0032] 5. Dewax the paraffin sections to water: put the sections into environmentally friendly dewaxing liquid I for 20 minutes, environmentally friendly dewaxing liquid II for 20 minutes, anhydrous ethanol I for 5 minutes, anhydrous ethanol II for 5 minutes, and 75% alcohol for 5 minutes, and wash with tap water.

[0033] 6. Pretreatment: Put the slices into high-definition constant staining pretreatment solution for 1 minute.

[0034] 7. Hematoxylin staining: Stain the sections with hematoxylin solution for 3 minutes, wash with tap water, differentiate with differentiation solution, wash with tap water, reblue with bluing solution, and rinse with running water.

[0035] 8. Eosin staining: Dehydrate the sections in 95% alcohol for 1 min and then stain them in eosin solution for 15 s.

[0036] 9. Dehydration and sealing: The slices were placed in anhydrous ethanol I for 2 min-anhydrous ethanol II for 2 min-anhydrous ethanol III for 2 min-n-butanol I for 2 min-n-butanol II for 2 min-xylene I for 2 min-xylene II for 2 min, and the slices were sealed with transparent neutral gum.

[0037] 10. Microscope examination, image acquisition and analysis.

[0038] The results are as follows Figure 1 As shown, Figure 1The following is a schematic diagram of the survival period and intestinal damage of S100A9 KO mice after radiation, where A is a schematic diagram of the comparison of the survival rate of the experimental group and the control group after radiation, B is a schematic diagram of the pathological HE staining results of the experimental group and the control group, and C is a schematic diagram of the results of the length and crypt depth of the small intestine of the experimental group and the control group. A shows that the survival rate of S100A9 knockout mice after radiation is significantly lower than that of the control group. B shows that compared with the control group, the pathological HE staining of the intestinal tract of mice after radiation shows that the small intestinal villi in the S100A9 KO group are broken, shortened, and reduced in number, with abnormal morphology, thinning of the mucosa, and a decrease in crypt epithelial cells. C shows that the length and crypt depth of the small intestinal villi in the S100A9 KO group after radiation are both lower than those in the control group. The above shows that the radiation sensitivity of S100A9 KO mice is increased, and the intestinal damage is more serious. S100A9 can be used as a potential new target for the development of drugs to prevent and treat radiation-induced intestinal injury.

[0039] Example 2

[0040] Exogenous administration of S100A9 recombinant protein (rm-S100A9, 2065-S9-050, R&D Systems) to mouse intestinal organoids can significantly enhance the ability of crypts to form organoids

[0041] The steps for culturing mouse intestinal organoids are as follows:

[0042] 1. Select 8-week-old C57BL / 6 mice and kill them by carbon dioxide asphyxiation. After soaking in 75% alcohol, extract 15 cm of small intestinal tissue under sterile conditions and cut it into small segments of 3 to 5 cm in length. Use a 1 ml pipette to suck cold PBS containing double antibodies from both ends of the small intestine to repeatedly flush the intestinal cavity, then cut it longitudinally and rinse the contents thoroughly.

[0043] 2. Cut the small intestinal tissue vertically into rice-sized pieces and place them in a six-well plate. Transfer them into a 50ml centrifuge tube with a pipette. Add 15ml of cold PBS containing double antibodies and rinse the supernatant by pipetting three times.

[0044] 3. Add 15 ml PBS / EDTA to the small intestinal tissue and shake rapidly at 200 rpm on an ice bath shaker for 1 hour. During this period, use a vortex shaker to vigorously shake 3 times every half an hour, each time lasting 1 minute, with an interval of 2 minutes.

[0045] 4. Filter the small intestinal tissue suspension with a 70μm filter, transfer the filtrate into a 15ml centrifuge tube, and centrifuge at 290G for 5 minutes at 4℃ to obtain the precipitate.

[0046] 5. Add 10 ml of cold PBS containing double antibodies to the cell pellet and resuspend it. Centrifuge at 200G for 5 minutes at 4°C. Wash it twice. The lower sediment after centrifugation is the small intestinal crypt cells.

[0047] 6. Preheat the 24-well plate in a cell culture incubator, prepare complete culture medium for later use, and then prepare mixed culture medium in a ratio of complete culture medium: matrix gel = 1:1.

[0048] 7. Mix the small intestinal crypt cells and mixed culture medium at a ratio of 1:50, then add 50 μl of the mixed cell solution to the center of each well in the preheated 24-well plate. After the culture medium solidifies for 30 minutes, add 0.5 ml of complete culture medium to each well and place in a cell culture incubator for the culture of small intestinal organoids.

[0049] 8. 12 hours before irradiation, the organoids were divided into experimental and control groups, and rmS100A9 ((5 ng / ml)) and equal volumes of PBS were added to each group. The organoids were then irradiated with 6 Gy at a dose rate of 1 Gy / min.

[0050] 9. Observe the growth daily and collect images after the organoids mature.

[0051] The results are as follows Figure 2 As shown, Figure 2 The figure is a schematic diagram of the results of exogenous administration of rm-S100A9 to mouse intestinal organoids and extraction of intestinal organoid RNA for QT-PCR, where A is a schematic diagram of intestinal organoid growth. The results show that administration of rm-S100A9 (5ng / ml) can significantly promote the ability of intestinal organoids to form after irradiation, and B is a statistical diagram of the relative area of ​​the organoids and the organoid budding rate. By observing the culture of small intestinal organoids, it was found that the administration of rm-S100A9 can improve the ability of crypts to form organoids in irradiated mice, which is manifested in that the number of crypt-formed organoids in the experimental group is increased compared with the control group, and the number of buds of a single organoid is increased and the volume is larger. And by extracting organoid RNA for QT-PCR verification, the results are shown in C in the figure. C is a schematic diagram of the results of extracting organoid RNA for qPCR verification. It can be seen from the figure that the intestinal stem cell marker Lgr5 and Paneth cell markers DLL4 and MMP7 in the S100A9 recombinant protein group are significantly upregulated. This indicates that the administration of rm-S100A9 has a protective effect on small intestinal organoids from radiation damage, can effectively promote the proliferation and differentiation of mouse small intestinal organoids after irradiation, and promote stem cell regeneration.

[0052] Example 3

[0053] S100A9 exerts radiation protection through NOTCH signaling pathway

[0054] The steps for culturing mouse intestinal organoids are as follows:

[0055] 1. Select 8-week-old C57BL / 6 mice and kill them by carbon dioxide asphyxiation. After soaking in 75% alcohol, extract 15 cm of small intestinal tissue under sterile conditions and cut it into small segments of 3 to 5 cm in length. Use a 1 ml pipette to suck cold PBS containing double antibodies from both ends of the small intestine to repeatedly flush the intestinal cavity, then cut it longitudinally and rinse the contents thoroughly.

[0056] 2. Cut the small intestinal tissue vertically into rice-sized pieces and place them in a six-well plate. Transfer them into a 50ml centrifuge tube with a pipette. Add 15ml of cold PBS containing double antibodies and rinse the supernatant by pipetting three times.

[0057] 3. Add 15 ml PBS / EDTA to the small intestinal tissue and shake rapidly at 200 rpm on an ice bath shaker for 1 hour. During this period, use a vortex shaker to vigorously shake 3 times every half an hour, each time lasting 1 minute, with an interval of 2 minutes.

[0058] 4. Filter the small intestinal tissue suspension with a 70μm filter, transfer the filtrate into a 15ml centrifuge tube, and centrifuge at 290G for 5 minutes at 4℃ to obtain the precipitate.

[0059] 5. Add 10 ml of cold PBS containing double antibodies to the cell pellet and resuspend it. Centrifuge at 200G for 5 minutes at 4°C. Wash it twice. The lower sediment after centrifugation is the small intestinal crypt cells.

[0060] 6. Preheat the 24-well plate in a cell culture incubator, prepare complete culture medium for later use, and then prepare mixed culture medium in a ratio of complete culture medium: matrix gel = 1:1.

[0061] 7. Mix the small intestinal crypt cells and mixed culture medium at a ratio of 1:50, then add 50 μl of the mixed cell solution to the center of each well in the preheated 24-well plate. After the culture medium solidifies for 30 minutes, add 0.5 ml of complete culture medium to each well and place in a cell culture incubator for the culture of small intestinal organoids.

[0062] 8. The organoids were divided into an experimental group and a control group. rmS100A9 (5 ng / ml), Dibenzazepine (DBZ) (0.05 μg / ml), and an equal volume of PBS were added to the organoids of the two groups, respectively. The organoids were then irradiated with 6 Gy at a dose rate of 1 Gy / min.

[0063] 9. Observe the growth daily and collect images after the organoids mature.

[0064] The results are as follows Figure 3 As shown, Figure 3 This is a schematic diagram of the results of exogenously administering rmS100A9 to mouse intestinal organoids and extracting intestinal organoid RNA for QT-PCR after blocking the Notch signaling pathway; Figure 3Figure A shows that after the experimental group was given the NOTCH signaling pathway inhibitor Dibenzazepine (DBZ; HY-13526, MedChemExpress) (0.05 μg / ml), it was found that the promoting effect of S100A9 recombinant protein on the proliferation and differentiation ability of mouse intestinal organoids was inhibited. Figure 3 Figure B shows that by extracting organoid RNA and performing QT-PCR verification, it was found that the ability of S100A9 recombinant protein to upregulate the expression of intestinal stem cells Lgr5, Ascl2, and Hes1 was also inhibited by Dibenzazepine regardless of irradiation conditions, indicating that S100A9 exerts its role in protecting the intestine from radiation damage through the NOTCH pathway.

[0065] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A use of S100A9 in the preparation of a drug for preventing or treating radiation-induced intestinal damage.

2. The use of S100A9 according to claim 1 in the preparation of a drug for preventing or treating radiation-induced intestinal damage caused by ionizing radiation, characterized in that: The ionizing radiation is the use of 60 Co γ-ray irradiation.

3. Use of S100A9 according to claim 1 in the preparation of a drug for preventing or treating radiation-induced intestinal damage caused by ionizing radiation, characterized in that: The irradiation dose of the ionizing radiation is 8.5 Gy, and the dose rate is 1.0 Gy / min.

4. The use of S100A9 according to claim 1 in the preparation of a drug for preventing or treating radiation-induced intestinal damage caused by ionizing radiation, characterized in that: In the application, S100A9 is the only active ingredient.

5. A pharmaceutical composition, characterized in that The invention is prepared from active components and pharmaceutically acceptable excipients; wherein the active component is S100A9.

6. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition is used in combination with other drugs for preventing or treating radiation-induced intestinal damage caused by ionizing radiation.

Citation Information

Cited By

  • Application of polypeptide in preparation of medicine for treating radioactive intestinal injury

    CN121102437A